Permanent Consequences in Langerhans Cell Histiocytosis Patients: A Pilot Study from the Histiocyte Society - Late Effects Study Group

Pediatric Blood and Cancer

Volumn 42, Issue 5, 2004, Pages 438-444

  Haupt, Riccardo ^a   Nanduri, Vasanta ^b   Calevo, Maria Grazia ^a   Bernstrand, Cecilia ^c   Braier, Jorge L ^d   Broadbent, Valerie ^e   Rey, Guadalupe ^f   McClain, Kenneth L ^g   Janka Schaub, Gritta ^h   Maarten Egeler, R ^i,j  

^a G GASLINI INSTITUTE   (Italy)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^g TEXAS CHILDREN S HOSPITAL   (United States)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ ALBERTA CHILDREN'S HOSPITAL   (Canada)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Endocrine problems; Langerhans cell histiocytosis; Long term survivors; Neurological complications; Toxicity

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADENOHYPOPHYSIS DISEASE; ATAXIA; BONE DISEASE; BONE LESION; CANCER INCIDENCE; CANCER SURVIVAL; CONVULSION; DIABETES INSIPIDUS; DYSARTHRIA; DYSESTHESIA; DYSMETRIA; ENDOCRINE DISEASE; EXOPHTHALMOS; EYE DISEASE; FOLLOW UP; GAIT DISORDER; GROWTH RETARDATION; HEARING LOSS; HISTIOCYTOSIS; HISTIOCYTOSIS X; HUMAN; HYDROCEPHALUS; INTELLECTUAL IMPAIRMENT; JAW DISEASE; LEG LENGTH INEQUALITY; LIVER DISEASE; LUNG DISEASE; MEDICAL SOCIETY; MENTAL DISEASE; NEUROLOGIC DISEASE; ONSET AGE; PERIODONTAL DISEASE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOMOTOR RETARDATION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCOLIOSIS; SECOND CANCER; SKIN DISEASE; SURVIVAL TIME; THYROID CARCINOMA; TREMOR; VERTEBRA MALFORMATION; VISUAL IMPAIRMENT;

ADOLESCENT; BONE AND BONES; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; DIABETES INSIPIDUS; FOLLOW-UP STUDIES; HEARING LOSS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; NEOPLASMS, SECOND PRIMARY; PILOT PROJECTS; PREVALENCE; PROBABILITY; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL;

EID: 11144357476     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20021     Document Type: Review

References (23)

1. Willman C, Busque L, Griffith BB, et al. Langerhans' cell histiocytosis (histiocytosis X), a clonal proliferative disease. N Engl J Med 1994;331:154-160.
2. Ceci A, De Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: Results from the Italian cooperative AIEOP-CNR-HX'83 Study. Med Pediatr Oncol 1993;21:259-264.
3. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994;23:72-80.
4. The French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child 1996; 75:17-24.
5. Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Pediatr 2000; 212:139-144.
6. Gadner H, Grois N, Aricò M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001; 138:728-734.
7. Lahey E. Histiocytosis X-An analysis of prognostic factors. J Pediatr 1975;87:184-189.
8. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
9. Haupt R, Fears TR, Heise A, et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in the Italian and Austrian-German populations. Int J Cancer 1997;71:9-13.
10. Komp DM. Long-term sequelae of histiocytosis X. Am J Pediatr Hematol Oncol 1981;3:165-168.
11. Komp DM, El Mahadi A, Starling KA, et al. Quality of survival in histiocytosis X: A Southwest Oncology Group study. Med Pediatr Oncol 1980;8:35-40.
12. Braier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: Retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol 1999;16:377-385.
13. Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol 1996; 14:2073-2082.
14. Nanduri V, Levitt G, Stanhope R, et al. Prevalence of late sequelae of multisystem Langerhans' cell histiocytosis-A single institution study [abstr]. Med Pediatr Oncol 1999;32:235.
15. Dunger DB, Broadbent V, Yeoman E, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med 1989;321:1157-1162.
16. Broadbent V, Pritchard J. Diabetes insipidus associated with Langerhans cell histiocytosis: Is it reversible? Med Pediatr Oncol 1997;28:289-293.
17. Nanduri VR, Bareille P, Pritchard J, et al. Growth and endocrine disorders in multisystem Langerhans' cell histiocytosis. Clin Endocrinol 2000;53:509-515.
18. Grois N, Flucher-Wolfram B, Heitger A, et al. Diabetes insipidus in Langerhans cell histiocytosis: Results from the DAL-HX 83 Study. Med Pediatr Oncol 1995;24:248-256.
19. Cervera A, Madero L, Garcia Penas JJ, et al. CNS sequelae in Langerhans cell histiocytosis: Progressive spinocerebellar degeneration as a late manifestation of the disease. Pediatr Hematol Oncol 1997;14:577-584.
20. Whitsett SF, Kneppers K, Coppes MJ, Egeler RM. Neuropsychologic deficits in children with Langerhans cell histiocytosis. Med Pediatr Oncol 1999;33:486-492.
21. Grois NG, Favara BE, Mostbeck GH, et al. Central nervous system disease in Langerhans cell histiocytosis, Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:287-305.
22. Barthez MA, Araujo E, Donadieu J. Langerhans cell histiocytosis and the central nervous system in childhood: Evolution and prognostic factors. Results of a collaborative study. J Child Neurol 2000;15:150-156.
23. Egeler RM, Neglia JP, Aricò M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am 1998;12:369-378.